Critical cardiovascular diseases
Conditions
Interventions
Experimental group:Combined use of pLVAD on the basis of VA-ECMO support
Sponsors
The First Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients aged 18-80 years with cardiogenic shock who have been treated with VA-ECMO, and the VA-ECMO is running smoothly, but the patient with situation of left ventricular overload (frequent episodes of acute left heart failure, invasive arterial pressure difference <10mmHg, limited aortic valve opening, left ventricular blood stasis, etc.) The definition of cardiogenic shock includes: (1) hypotension: SBP<90mmHg or MAP <60mmHg, or the need for vasoactive drugs to maintain SBP=90mmHg or MAP =60mmHg; (2) low cardiac output (despite adequate preload); (3) Tissue hypoperfusion: altered mental status, clammy or spotted limbs, oliguria or anuria, and elevated lactate level.
Exclusion criteria
Exclusion criteria: (1)CPR; (2) severe pulmonary embolism; (3) severe right heart failure; (4) left ventricular wall thrombosis; (5) Ventricular septum or atrial septal defect; (6) cardiac rupture; (7) Pericardial tamponade; (8) Severe aortic valve disease: severe aortic regurgitation; severe aortic stenosis; severe aortic valve calcification; mechanical aortic valves; (9) Severe aortic disease: aortic dissection, etc.; (10) Severe peripheral vascular disease that makes it impossible for the experimental product to intervene; (11) History of chronic cardiopulmonary diseases; (12) It has a cardiac contraction regulator; (13) Hematologic diseases that can easily lead to hemolysis; (14) pregnancy; (15) Other circumstances judged by the investigator to be unsuitable for participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 30-day survival rate after hospital discharge; | — |
Secondary
| Measure | Time frame |
|---|---|
| Successful weaning rate of VA-ECMO;Successful weaning rate of pLVAD;In-hospital survival rate;Survival rate at 3 months after discharge;Survival rate at 6 months after discharge;Survival rate at 1 year after discharge;The success rate of bridging to long-term therapy (long-term VAD or heart transplant);Incidence of hemolysis;transfusion;Incidence of bleeding;Vascular complication rate;Incidence of lower extremity ischemia;Incidence of ischemic stroke;Incidence of renal failure or CRRT; | — |
Countries
China
Contacts
Public ContactMing Bai
The First Hospital of Lanzhou University
Outcome results
None listed